Neutropenia ( ten [ 2 % ] vs 29 [ 16 % ] ) , diarrhoea ( three [ < 1 % ] vs eight [ 4 % ] ) , and febrile neutropenia ( one [ < 1 % ] vs seven [ 4 % ] ) were grade 3 or worse adverse events that were more common in the physician 's choice group than in the trastuzumab emtansine group .